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In vitro studyMalaria (Plasmodium spp.) andhumanAfrican trypanosomiasis (Trypanosoma brucei spp.) are vector borne, deadly
parasitic diseases. While chemotherapeutic agents for both diseases are available, difﬁculty in disease eradication
and development of drug resistance require that new therapies targeting unexplored pathways or exploiting novel
modes of action be developed. Intracellular Plasmodium and extracellular Trypanosoma brucei may have unique
and essential requirements for divalent metal ions, beyond that deemed physiological for the host. Membrane
Active Chelators (MACs), biologically active only in a hydrophobic lipid environment, are able to bind metal ions
at elevated non-physiological concentrations in the vicinity of cell membranes. A dose–response relationship
study using validated viability assays revealed that two MAC drugs, DP-b99 and DP-460, were cytotoxic for
these parasites in vitro. The 50% effective concentration (EC50) values for DP-b99 and DP-460 were 87 μM and
39 μM for Trypanosoma brucei brucei and 21 μM and 28 μM for erythrocytic Plasmodium falciparum, respectively.
Furthermore, drug potency was maintained for at least 24 h in serum containing medium at 37 °C. While the
exact mechanism of action of MACs against intracellular malaria and extracellular African trypanosome parasites
has yet to be determined, their potential as antiparasitic agents warrants further investigation.
© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Malaria (Plasmodium spp.) and human African Trypanosomiasis
(HAT) are vector borne diseases that are among the most deadly para-
sitic diseases, for the sheer number of people killed annually (malaria)
or for the near 100% fatality rate when untreated (HAT). Malaria afﬂicts
hundreds of millions of people and causes over a million deaths each
year. Malaria is transmitted by mosquitoes and caused by intracellular
protozoan parasites from the genus Plasmodium. By far the most signif-
icant species is Plasmodium falciparum, which causes severe infections
and death, enjoys widespread geographic distribution, and is most like-
ly to be drug resistant. Malaria now features prominently among the
“reemerging” infectious diseases. The impact of falciparum malaria is
likely to increase since the parasite is resistant to most clinically used
drugs. The artemisinins are the only drug class retaining widespread
effectiveness; however, their efﬁcacy has recently come under threat
in South-east Asia [1]. The tsetse ﬂy transmitted African trypanosomesThe Johns Hopkins University
21205, USA. Tel.: +1 410 955
reland Ltd. Open access under CC BY-NTrypanosoma brucei rhodesiense and Trypanosoma brucei gambiense
cause human African trypanosomiasis (HAT, commonly called sleeping
sickness); the closely related subspecies Trypanosoma brucei brucei
causes animal trypanosomiasis and is frequently used in the laboratory.
These parasites play an important and sometimes devastating role in
the health and welfare of people and cattle throughout the large areas
of sub-Saharan Africa [2]. HAT is one of the most deadly of the
so-called “neglected” tropical diseases, because death is inevitable in
absence of treatment. Currently, only 5 drugs are available for the treat-
ment of HAT — pentamidine, suramin, eﬂornithine, melarsoprol and
nifurtimox [3]. Not all drugs act against all stages of the diseases. Addi-
tionally, the incidence of treatment-refractory infections is increasing.
For bothmalaria and HAT, new therapies targeting novelmechanisms
andpathways are urgently needed. Calcium ions (Ca2+) are important for
control and maintenance of many cellular functions. For eukaryotic or-
ganisms, extracellular Ca2+ levels are typically 104 times higher than in
the cytoplasm. Intracellular free calcium – [Ca2+]i – is tightly controlled
by several spatially and temporally organized Ca2+-transporting systems
[4]. To maintain resting [Ca2+]i concentrations in low nM ranges, cells
prevent Ca2+ from ﬂooding the cytoplasm by i) utilizing ATP and special
Ca2+ pumps and ii) tightly controlled passage of Ca2+ through Ca2+
channels and exchangers. Any disturbances to these tightly control path-
ways result in negative consequences, including cell death. To be effectiveC-ND license.
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targeting Ca2+ handling will have to target something unique to the
parasites. Plasmodium and trypanosomes, like mammalian cells, contain
the major Ca2+-binding protein calmodulin (CaM) and several EF-hand
(Ca2+-binding motif) proteins such as P. falciparum PfCDPK1-1 and
PfS40/PfERC, and Trypanosoma brucei IFH5, Tb-17, Tb24 and Tb44 [5].
However, the acidocalcisome is likely to provide a better selective target.
Present in kinetoplastid and apicomplexan parasites, acidocalcisomes
are acidic organelles and large reservoirs for Ca2+ and Zn2 complexed
to polyphosphates and pyrophosphates [5]. Rich in ion exchangers, ion
pumps and aquaporins, acidocalcisomes help maintain pH homeostasis
and osmoregulation and are considered important chemotherapeutic
targets [6,7]. Ca2+ is also required for cell invasion by P. falciparum and
interference with cell signaling pathways to subvert the host intracellu-
lar milieu; this is an important mechanism for P. falciparum's survival
within host cells [8,9] and for egress [10]. During egress, the parasites
ﬁrst weaken the host's red blood cell (RBC) membrane by removing a
selected set of cytoskeletal adaptor proteins and then in a Ca2+ depen-
dent manner use host calpain-1 to dismantle the remaining cytoskele-
ton, leading to RBC membrane collapse and egress [10].
The Membrane Activated Chelators (MACs) DP-b99 and DP-460,
diester derivatives of BAPTA [1,2-bis(2-aminophenyloxy)ethane-N,
N,N′,N′-tetraacetic acid], represent a new class of neuroprotective
drugs that modulate cell membrane metal ion homeostasis (Fig. 1).
These compounds adopt an inactive conformation in an aqueous
environment outside the cell, and become biologically active and bind
metal ions only when associated with lipid cell membranes. Thus, the
drug is active only at the site of action resulting in excellent systemic
tolerability [11–13]. The ability of DP-b99 to chelate metal ions, only
in a hydrophobic environment, was shown in vitro [14]. In regulatory
required preclinical animal toxicology studies, there was no evidence
for hemolysis even after repeated daily administration of DP-b99 at
doses 6–12 times higher than the clinical dose (1 mg/kg) in humans
(D-Pham; unpublished data). DP-b99 is a MAC of Ca2+ and Zn2+,
which is safe in humans [11–13]. DP-b99 has been shown to protect
neurons against a toxic Zn2+-rise by effectively attenuating Zn2+ and
Ca2+ surges [15]. DP-b99 exerts its effect on metal dependent, mem-
brane associated enzymes e.g. TACE (TNF-α converting enzyme) and
MMP9 (matrix metalloprotease 9) (D-Pharm; data not shown). Unlike
the chelating agent clioquinol, MACs however, have no effect on theFig. 1.Membrane activated chelators (MACs). The structure of DP-b99 (832 Da) (A) and DP-
that sequester metals in aqueous environments (I) are of limited use as therapeutic agents as th
aqueous environments (II), but permit the selective sequestration of metal ions in the vicinityactivity ofmetal dependent enzymes located in the cytoplasm, e.g. angio-
tensin converting enzyme (D-Pharm: unpublished data). The tolerability
and efﬁcacy of a related orally active compound DP-460 showed promis-
ing efﬁcacy in an amyotrophic lateral sclerosis mouse model [16].
MACs do not act as a detergent and are not damaging to red blood
cells as judged by extensive long term in vivo toxicology studies enabling
clinical studies in man [11–13], rather they affect metal dependent pro-
cesses that are associatedwith themembrane [14]. Considering that pro-
tozoan parasitesmight have unique and essential requirements for Ca2+
and Zn2+ beyond what would be deemed physiological for the host but
required for Plasmodium invasion/survival/egress of host cells or needed
by extracellular African trypanosomes (T. b. brucei/T. b. rhodesiense), we
hypothesized that the parasites would likely be vulnerable to the effect
of MACs.
We assayed the effect of MACs in a validated in vitro in a 96 well plate
cytotoxicity assay utilizing bloodstream-form T. b. brucei 427 [17]. We
ﬁnd that DP-b99 andDP-460 are trypanocidal at lowmicromolar concen-
trations (Fig. 2). The 50% effective concentration (EC50) values in 24 h
were 87 μMforDP-b99 (Fig. 2A) and 39 μMforDP-460 (Fig. 2C). Interest-
ingly, parasites were no longer seen after 3–4 h incubation with higher
MAC concentrations; i.e., ~110 μM. This suggests that MACs may, indeed,
be cytotoxic (cytolytic) towards T. brucei. Similar EC50 values were found
with T. b. brucei and human CSF isolate T. b. rhodesiense IL-1852 using a
qualitative phenol red-based cell death assay [18,19]: 65 μM for DP-b99
and 40 μM for DP-460 for T. b. brucei and 41 μM for DP-b99 and
27 μM for DP-460 for T. b. rhodesiense. In antimalarial assays [20],
MACs DP-b99 (Fig. 2B) and DP-460 (Fig. 2D) were also potent against
human erythrocytic P. falciparum, with EC50 values of 21 μM and
28 μM respectively. Drug potency was maintained for at least 24 h in
serum containing medium at 37 °C, or when stored at 5 °C for at least
28 days as a 50 mg/mL solution in DNAse/RNAse free water (Promega).
The mechanism of action of MACs against intracellular malaria and
extracellular African trypanosome parasites is a matter of speculation.
It is possible that the binding of MACs to the plasma membranes of
free-swimming trypanosomes or extracellularmerozoites could disrupt
Ca2+ homeostasis leading to parasite cytotoxicity. The binding of MACs
to RBC plasmamembranesmight prevent plasmodiummerozoite bind-
ing, block calpain-dependent egress, and/or be directly cytotoxic to
intracellular parasites thus enhancing MACs efﬁcacy. MACs may also
inhibit parasite growth by selectively triggering Ca2+-signaling cascade460 (945.2 Da) (B) lipophilic divalent transition metal chelators. (C) Metal ion chelators
eymay cause cardio-toxicity. Lipid tails present inMACs hinder their chelating function in
of the cell membrane (III).
A) T. brucei + DP-b99 B) P. falciparum + DP-b99
C) T. brucei + DP-460 D) P. falciparum + DP-460
Fig. 2. Antiparasitic activity of MACs in vitro. Bloodstream-form T. brucei (MiTat 1.2, strain 427) were incubated with DP-b99 (A) or DP-460 (C). Cells were exposed to varying concen-
trations of drug for 24 h, and surviving cells were detected by the acid phosphatase assay [17]. For each drug concentration (assayed in quadruplicate), all coefﬁcients of variation
were less than 3.5% and averaged 1.7%. P. falciparum NF54-infected human erythrocytes were incubated with DP-b99 (B) or DP-460 (D). Cells were exposed to drug for a total of 72 h
in a 96 well plate. At 48 h, [3H]hypoxanthine was added to the wells. Cell viability at the end of the incubation was assessed by incorporation of radioactivity into parasite nucleic
acids [20]. For each drug concentration (assayed in quadruplicate), all coefﬁcients of variation were less than 53% and averaged 7.0%. R2 values for all assays exceeded 0.992.
463D.J. Grab et al. / Parasitology International 62 (2013) 461–463dysfunction in free-swimming (T. brucei BSF or P. falciparummerozoites)
and intracellular (erythrocytic P. falciparum), likely via the unique
acidocalcisome.
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